Among them, Orlistat that prevents enteric lipid absorption is targeting obesity, and acts as a reversible lipase inhibitor [37]; Thiazolidinediones, the PPARγ agonists, are proved to be effective in enhancing insulin sensitivity [38]; The lipid-lowering agent statin is mostly used in treating dyslipidemia and mainly regulating cholesterol synthesis [39]; Obeticholic acid, a synthetic variant of chenodeoxycholic acid, is a potent activator of the farnesoid X nuclear receptor, and has been confirmed to improve NASH pathology [40]. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.